Gilead Sciences's most recent trend suggests a bullish bias. One trading opportunity on Gilead Sciences is a Bull Put Spread using a strike $80.00 short put and a strike $75.00 long put offers a potential 9.65% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $80.00 by expiration. The full premium credit of $0.44 would be kept by the premium seller. The risk of $4.56 would be incurred if the stock dropped below the $75.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Gilead Sciences is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Gilead Sciences is bullish.
The RSI indicator is at 75.19 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
Stock-Picking Increasingly Critical in Health Care
Sat, 28 Jun 2014 11:00:00 GMT
Biotech and pharma sector outlook
Fri, 27 Jun 2014 21:16:00 GMT
Gilead Sciences: Big in Japan
Fri, 27 Jun 2014 13:43:00 GMT
3:07 am Gilead Sciences submits New Drug Application to Japan's pharmaceutical and Medical Devices Agency for Sofosbuvir for chronic Hepatitis C
Fri, 27 Jun 2014 07:07:00 GMT
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C
Fri, 27 Jun 2014 07:01:00 GMT
Business Wire – FOSTER CITY, Calif.–(BUSINESSWIRE)– Gilead Sciences, Inc. (Nasdaq:GILD – News) today announced that the company has submitted a New Drug Application (NDA) to Japan’s Pharmaceutical and Medical Devices Agency (PMDA) for approval of sofosbuvir, a once-daily nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The data in the NDA support the use of sofosbuvir with ribavirin (RBV) for 12 weeks in patients with genotype 2 HCV infection.
Related Posts
Also on Market Tamer…
Follow Us on Facebook